Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and
a tragedy. JAMA.1989;261:737-743.
Gay JD, Donaldson LD, Goellner JR. False negative results in cervical cytologic studies. Acta Cytol.1985;29:1043-1046.
National Cancer Institute. The 1988 Bethesda system for reporting cervical/vaginal cytological
Sasieni PD, Cuzick J, Lynch-Framery E. Estimating the efficacy of screening by auditing smear histories of
women with and without cervical cancer. Br J Cancer.1996;73:1001-1005.
Confortini M, Biggeri A, Cariaggi MP.
et al. Intralaboratory reproducibility in cervical cytology: results of the
application of a 100-slide set. Acta Cytol.1993;37:49-54.
Klinkhamer PJ, Vooijs GP, de Haan AF. Intraobserver and interobserver variability in the diagnosis of epithelial
abnormalities in cervical smears. Acta Cytol.1988;32:794-800.
Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic
interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA.2001;285:1500-1505.
Solomon D, Schiffman M, Tarone B.for the ALTS Group. Comparison of three management strategies for patients with atypical
squamous cells of undetermined significance (ASCUS): baseline results from
a randomized trial. J Natl Cancer Inst.2001;93:293-299.
International Agency for Research on Cancer (IARC) Working Group on
the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon, France: World Health Organization; 1995. IARC Monographs on
the Evaluation of Carcinogenic Risks to Humans. Vol 64.
Bosch FX, Manos MM, Munoz N.
et al. Prevalence of human papillomavirus in cervical cancer: a worldwide
perspective. J Natl Cancer Inst.1995;87:796-802.
Koutsky LA, Holmes KK, Critchlow CW.
et al. A cohort study of the risk of cervical intraepithelial neoplasia grade
2 or 3 in relation to papillomavirus infection. N Engl J Med.1992;327:1272-1278.
Ho GY, Burk RD, Klein S.
et al. Persistent genital human papillomavirus infection as a risk factor
for persistent cervical dysplasia. J Natl Cancer Inst.1995;87:1365-1371.
Wallin KL, Wiklund F, Angstrom T.
et al. Type-specific persistence of human papillomavirus DNA before the development
of invasive cervical cancer. N Engl J Med.1999;341:1633-1638.
Cuzick H, Beverley E, Ho L.
et al. HPV testing in primary screening of older women. Br J Cancer.1999;81:554-558.
Cuzick J, Szarewski A, Terry G.
et al. Human papillomavirus testing in primary cervical screening. Lancet.1995;345:1533-1536.
Ratnam S, Franco E, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer
precursors. Cancer Epidemiol Biomarkers Prev.2000;9:945-951.
Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou
smears: a meta-analysis of prospective studies comparing cytologic diagnosis
and sample adequacy. Am J Obstet Gynecol.2001;185:308-317.
Manos MM, Kinney WK, Hurley LB.
et al. Identifying women with cervical neoplasia using human papillomavirus
DNA testing for equivocal Papanicolaou results. JAMA.1999;281:1605-1610.
Luff RD. The Bethesda system for reporting cervical/vaginal cytologic diagnoses:
report of the 1991 Bethesda Workshop. Hum Pathol.1992;23:719-721.
Center for Devices and Radiological Health, US Food and Drug Administration. Clinical Laboratory Improvement Methods. 2002. Available at: http://www.fda.gov/cdrh/clia. Accessibility
verified September 13, 2002.
Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types using L1 consensus PCR
products by a single hybridization reverse line-blot detection method. J Clin Microbiol.1998;36:3020-3027.
Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993:436.
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. Detection of high risk HPV types by the signal amplification 2 test. J Med Virol.2001;65:155-162.
Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM. Comparison of PCR- and hybrid capture-based human papillomavirus
detection systems using multiple cervical specimen collection strategies. J Clin Microbiol.1998;36:3248-3254.
ALTS Group. Human papillomavirus testing as a triage strategy for women with cytologic
evidence of low grade squamous intraepithelial lesions: baseline data from
a randomized trial. J Natl Cancer Inst.2000;92:397-402.
Eger RR, Peipert JF. Risk factors for non-compliance in a colposcopy clinic. J Reprod Med.1996;41:671-674.
Paskett ED, Phillips KC, Miller ME. Improving compliance among women with abnormal Papanicolaou smears. Obstet Gynecol.1995;86:353-359.
Schneider A, Hoyer H, Lotz B.
et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer
by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer.2000;89:529-534.
Khanna N, Phillips MD. Adherence to care plan in women with abnormal Papanicolaou smears:
a review of barriers and interventions. J Am Board Fam Pract.2001;14:123-130.